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Tie2 activation promotes choriocapillary  
regeneration for alleviating neovascular age-related 
macular degeneration
Jaeryung Kim1,2,3*, Jang Ryul Park4,5*, Jeongwoon Choi1,2, Intae Park1,2, Yoonha Hwang5,6, 
Hosung Bae1,2, Yongjoo Kim4,5, WooJhon Choi5, Jee Myung Yang2, Sangyeul Han1,  
Tae-Young Chung3, Pilhan Kim5,6, Yoshiaki Kubota7, Hellmut G. Augustin8,9,  
Wang-Yuhl Oh4,5†, Gou Young Koh1,2†
Choriocapillary loss is a major cause of neovascular age-related macular degeneration (NV-AMD). Although vas-
cular endothelial growth factor (VEGF) blockade for NV-AMD has shown beneficial outcomes, unmet medical 
needs for patients refractory or tachyphylactic to anti-VEGF therapy exist. In addition, the treatment could exacer-
bate choriocapillary rarefaction, necessitating advanced treatment for fundamental recovery from NV-AMD. In 
this study, Tie2 activation by angiopoietin-2–binding and Tie2-activating antibody (ABTAA) presents a therapeutic 
strategy for NV-AMD. Conditional Tie2 deletion impeded choriocapillary maintenance, rendering eyes susceptible 
to NV-AMD development. Moreover, in a NV-AMD mouse model, ABTAA not only suppressed choroidal neovascular-
ization (CNV) and vascular leakage but also regenerated the choriocapillaris and relieved hypoxia. Conversely, 
VEGF blockade degenerated the choriocapillaris and exacerbated hypoxia, although it suppressed CNV and vas-
cular leakage. Together, we establish that angiopoietin-Tie2 signaling is critical for choriocapillary maintenance 
and that ABTAA represents an alternative, combinative therapeutic strategy for NV-AMD by alleviating anti-VEGF 
adverse effects.
INTRODUCTION
Neovascular age-related macular degeneration (NV-AMD) is a lead-
ing cause of irreversible vision loss among elderly persons in devel-
oped countries (1). NV-AMD is characterized by the formation of 
choroidal neovascularization (CNV), an ingrowth of abnormal blood 
vessels from the choroid through Bruch’s membrane into the sub- 
retinal pigment epithelium (RPE) or subretinal space (2). Through-
out this ingrowth, abnormal leakages of fluids and bloods occur 
into the retina, causing vision distortion and loss of central vision 
(2, 3). To treat neovascular eye diseases including NV-AMD, anti–
vascular endothelial growth factor A (VEGF) therapy has largely been 
used based on the fact that an excessive production of VEGF from 
hypoxic cells in the retino-choroidal complex is critical in the patho-
genesis and features of neovascular eye diseases (3, 4). Nevertheless, 
intravitreal anti-VEGF therapy only temporarily suppresses CNV 
and its vascular leakage in NV-AMD, necessitating periodic and 
repeated administrations for several years (5). There have been con-
troversies on the adverse effects of long-term and repetitive anti- 
VEGF therapy. Although some studies have reported that frequent, 
chronic anti-VEGF injection is effective and safe (6, 7), others have 
had a long-standing concern that this long-term anti-VEGF therapy 
can arrest the normal repair processes in the NV-AMD and aggra-
vate hypoxia and oxidative stress in the retino-choroidal complex, 
leading to RPE damage, photoreceptor degeneration, and permanent 
vision loss (8–11).
The choriocapillaris, the innermost layer of the choroid, is a spe-
cialized vascular structure in the eye that functions as the major blood 
supply for the outer retina including photoreceptors and the RPE 
(12). Together with hypoxia, oxidative stress and inflammation in 
the RPE (2), loss of the choriocapillaris, and subsequent reduction 
in blood supply have been postulated to be the main initial insults in 
the development of NV-AMD by making adjacent outer retinal lay-
ers hypoxic (2, 13, 14). Previous studies (10, 11) revealed that VEGF 
is a critical regulator for maintaining the choriocapillaris in the adult 
eye. Therefore, an intensive VEGF blockade strategy would be det-
rimental to choriocapillary maintenance by preventing the trophic 
effect of VEGF, aggravating the initial insult that triggered NV-AMD. 
To avoid or relieve the adverse effects of anti-VEGF therapy on the 
maintenance of the choriocapillaris, RPE, and photoreceptors, a de-
sirable aim is an alternative, combinative strategy that promotes 
adequate regeneration of the choriocapillary vascular network.
The angiopoietin (Angpt)–Tie2 system functions as a key regu-
lator of vascular maturation and homeostasis (15). In accordance 
with this concept, vascular stabilization through Tie2 activation by 
vascular endothelial–phosphotyrosine phosphatase (VE-PTP) inhib-
ition or COMP-Ang1 prevents vascular leakage from the CNV and 
lessens retinal edema (16, 17). Tie2 activation also induces a healthy 
neovascularization without leakage and inflammation, which is a 
critical process for proper tissue regeneration (18). However, it is 
unknown whether Tie2 activation can induce regeneration of im-
paired choriocapillaris in NV-AMD, and a Tie2 activation strategy 
could be a potential therapeutic option for treating NV-AMD, espe-
cially for cases that are refractory or tachyphylactic to anti-VEGF 
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therapy. Also unknown are the roles of Angpt-Tie2 signaling in the 
maintenance of choriocapillary integrity.
Here, we demonstrate that the Angpt-Tie2 system is continuous-
ly required to maintain the integrity of adult choriocapillaris. Using 
our recently developed dual-functioning antibody, ABTAA (Angpt2- 
binding and Tie2-activating antibody) (19, 20), we show that Tie2 
activation by intravitreal administration of ABTAA confers crucial 
and multiple benefits including suppressions of the CNV and vas-
cular leakage, choriocapillary regeneration, and relief of hypoxia 
surrounding the CNV. These results point to the potential for an 
alternative, combinative treatment for NV-AMD.
RESULTS
Impaired Angpt1-Tie2 signaling during adulthood leads to 
choriocapillary loss and visual impairment
To gain insight into the role of Angpt1-Tie2 signaling in the main-
tenance of the choriocapillaris, we first examined Tie2 levels in the 
choriocapillaris of adult humans, which were obtained from the 
healthy cadaveric donor eyes for corneal transplantations. Relative-
ly high levels of Tie2 were detected in choriocapillary endothelial 
cells (ECs) in young adult humans (mean age, 30.8 years; range, 20 
to 36 years; n = 5), but the Tie2 level and choriocapillary density 
were reduced in older individuals (mean age, 71.2 years; range, 65 to 
84 years; n = 5) (Fig. 1, A to C). Thus, the reduction in Tie2 by the 
ageing process could be one of the contributing factors for the patho-
genesis of NV-AMD. We also examined expressions of Tie2 and 
Angpt1 in adult choroid using Tie2-GFP (green fluorescent protein) 
and Angpt1-GFP reporter mice (21). Tie2 expression was highly en-
riched in ECs, but Angpt1 expression was highly enriched in NG2+ 
perivascular cells surrounding choroidal vessels (fig. S1, A and B).
To investigate the role of Tie2 in the adult choriocapillaris, we 
generated a Tie2iEC mouse by crossing the Tie2flox/flox mouse (22) 
with the VE-cadherin-Cre-ERT2 mouse (23) and deleted Tie2 from 
ECs of the choriocapillaris from 8-week-old animals by tamoxifen 
administration (Fig. 1D). Cre-ERT2–positive but flox/flox–negative 
mice among the littermates were defined as wild-type (WT) mice. 
Although the choriocapillaris has the largest blood flow by weight 
in all organs (12), a detailed morphologic and functional analysis of 
it is extremely difficult in mice. To overcome these limitations, we 
used a newly developed optical coherence tomography angiography 
(OCTA) method (20). This advanced method allows not only a non-
invasive and detailed visualization of blood-perfused capillary vas-
cular networks of retina and choroid but also temporal monitoring 
in the same mouse (20). We performed intravital OCTA on the same 
day and at 4 and 8 weeks after initiation of tamoxifen administra-
tion (Fig. 1C) and calculated the relative retinal and choroidal blood 
flow from en face images exhibiting the retinal and choroidal layer, 
respectively (fig. S2). Consistent with previous findings (24, 25), no 
significant differences were found in the retinal blood flow between 
Tie2iEC mice and WT mice over the time points (Fig. 1, E to G). In 
contrast, the choroidal blood flow was reduced by 18.8 to 19.0% in 
Tie2iEC mice 4 and 8 weeks later, while it was unchanged in WT 
mice (Fig. 1, E, F, and H). Moreover, CD144+ adherens junctions in 
the choriocapillary ECs were reduced by 25.2 and 46.0% in Tie2iEC 
mice compared with WT mice 8 weeks later (Fig. 1, I and J). To ex-
clude the possibility of elevated intraocular pressure (IOP) as a cause 
of the reduced choroidal blood flow in the Tie2iEC mice (25), we 
adapted the microbeads-induced ocular hypertension model (26). 
Although IOP was elevated up to 15 to 20 mmHg in this model, no 
significant reduction of choroidal blood flow was detected (fig. S3, 
A to F).
Given that the choriocapillaris is a major vessel for supplying 
blood to the outer retina including photoreceptors, we analyzed the 
photoreceptor function in mice using electroretinography (ERG). 
Compared to WT mice, Tie2iEC mice showed marked attenuation 
of photopic b-wave by 39.3 to 44.8%, at a range of stimulus inten-
sities from 0.4 to 2.2 log cd·s/m2, indicating impairment of cone 
photoreceptors (Fig. 2, A, B, and D). Moreover, cone photoreceptor 
outer segment density was reduced by 41.4% in the outer retina of 
Tie2iEC mice (Fig. 2, G and H). On the other hand, no significant 
changes were observed in the function and the density of rod photo-
receptors (Fig. 2, C, E to G, and I). In addition, differences in opsin 
and rhodopsin protein expressions of retinas of Tie2iEC and WT 
mice were validated. In comparison with those of WT mice, retinas 
of Tie2iEC mice displayed reduced expression of opsin by 51.6% 
(Fig. 2, J and K). However, the rhodopsin level was not different 
between Tie2iEC and WT mice (Fig. 2, J and L). To confirm these 
findings, we examined whether the Tie2iEC mice has the mutations 
associated with photoreceptor degeneration including cng3, abca4, 
and pde6b (the rd1 mouse). The mice carried none of these mutations, 
suggesting that the photoreceptor degeneration in the Tie2iEC mice 
is caused by loss of the choriocapillaris and reduced blood supply.
To determine the role of Angpt1 in choriocapillaris maintenance 
during adulthood, we generated an Angpt1i/ mouse by crossing 
the Angpt1flox/flox mouse (27) with the ubiquitin-Cre-ERT2 mouse. 
Similar to Tie2iEC mice, Angpt1i/ mice also showed a gradual 
decrease in the choroidal blood flow by 22.2 to 23.7% during the 
follow- up period and reduced adherens junctions in choriocapillaris 
compared to those of WT mice (fig. S4, A to G). Moreover, cone 
photoreceptor density and photopic b-wave amplitude were also 
reduced in Angpt1i/ mice (fig. S5, A to I). These findings indicate 
that Angpt1-Tie2 signaling is indispensable for maintenances of the 
choriocapillaris and cone photoreceptors.
Tie2 depletion during adulthood exacerbates CNV formation 
and suppresses choriocapillary regeneration surrounding 
the CNV lesions
These findings led us to ask whether Tie2 deletion worsens the patho-
genesis of NV-AMD. To answer this question, we used a mouse 
model of laser-induced CNV that mimics human NV-AMD (28), 
with some modifications (16), although it is not fully consistent with 
the pathogenesis of human NV-AMD. We deleted Tie2 in ECs by 
tamoxifen administration to 8-week-old Tie2iEC mice, performed 
laser photocoagulation on retinas to rupture the RPE and Bruch’s 
membrane at 12 weeks, and performed intravital OCTA at 7 days 
(D7) after laser injury and at D14, D21, and D35 (Fig. 3A). The rel-
ative volumes of CNV and the avascular space surrounding the site 
of laser injury were calculated from en face images exhibiting the 
outer retinal and choroidal layers, respectively.
There was a moderate reduction in CNV volume in the outer 
retinas of WT mice, but those of Tie2iEC mice showed some in-
crease in CNV volume (Fig. 3, B to D). Compared with D7, Tie2 
depletion increased the avascular volume in choroids by 16.7, 14.0, 
and 29.5% at D14, D21, and D35, respectively. On the other hand, 
choroids of WT mice showed a reduction in the avascular volume 
by 20.6, 26.8, and 37.4%, respectively (Fig. 3, B, C, and E). These 
findings indicate that Tie2 deletion exacerbated CNV formation 
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Fig. 1. Tie2 deletion in adult ECs leads to damage and loss of choriocapillaris. (A to C) Images and comparisons of density and TIE2 intensity of CD31+ choriocapillaris 
in healthy young adult (20 to 36 years old; Y) and old adult (65 to 84 years old; O) human subjects. Error bars represent means ± SD. Each group, n = 5. *P < 0.05 versus 
Young by Mann-Whitney U test. Scale bars, 75 m. (D) Diagram of schedule for EC-specific depletion of Tie2 in 8-week-old mice and intravital OCTA at 8, 12, and 16 weeks 
(w) of age using Tie2iEC mice. (E and F) En face OCT angiograms showing retinal blood flow (left) and choroidal blood flow (middle) acquired by longitudinal OCTA imag-
ing of eyes. Each area marked by a white box is magnified in the corner. Each area marked by a yellow box is magnified on the right panel. (G and H) Temporal changes 
in relative retinal (G) and choroidal (H) blood flow. Error bars represent means ± SD. Each group, n = 10. **P < 0.005 versus WT by unpaired Student’s t test. (I and J) Images and 
comparison of CD144 intensity in CD31+ choriocapillaris. Error bars represent means ± SD. Each group, n = 5. *P < 0.05 versus WT by Mann-Whitney U test. Scale bars, 20 m.
 o
n
 April 15, 2019
http://advances.sciencem
ag.org/
D
ow
nloaded from
 
Kim et al., Sci. Adv. 2019; 5 : eaau6732     13 February 2019
S C I E N C E  A D V A N C E S  |  R E S E A R C H  A R T I C L E
4 of 16
Fig. 2. Loss of cone photoreceptor and subsequent visual impairment in EC-specific Tie2-depleted mice. (A) Diagram for EC-specific depletion of Tie2 in 8-week-old 
mice and analyses 2 months later using Tie2iEC mice. (B and C) Representative wave responses of ERG in photopic (B) and scotopic (C) conditions. (D) Comparisons of 
b-wave amplitude in photopic condition. Error bars represent mean ± SD. Each group, n = 6. **P < 0.005 versus WT by Mann-Whitney U test. (E and F) Comparisons of a- 
and b-wave amplitudes in scotopic condition. Error bars represent mean ± SD. Each group, n = 6. (G to I) Expression of opsin and rhodopsin in photoreceptor layer. Error 
bars represent mean ± SD. Each group, n = 6. *P < 0.05 versus WT by Mann-Whitney U test. Scale bars, 20 m. ONL, outer nuclear layer; OS, outer segments of photorecep-
tor cells; DAPI, 4′,6-diamidino-2-phenylindole. (J to L) Immunoblot detection of opsin and rhodopsin proteins. Densitometric analyses of the relative level of opsin and 
rhodopsin are shown. Each group, n = 4. *P < 0.05 versus WT by Mann-Whitney U test. GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
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Fig. 3. Tie2 deletion in adult ECs exacerbates CNV formation and hinders regeneration of choriocapillaris surrounding the CNV lesions. (A) Diagram of schedule 
for EC-specific depletion of Tie2 in 8-week-old mice, induction of CNV after 4 weeks (D0), and intravital OCTA at D7, D14, D21, and D35 using Tie2iEC mice. (B and C) En 
face OCT angiograms and selected cross-sectional OCT angiograms of the locations indicated by white dotted lines showing inner retinal blood flow (blue), outer retinal 
blood flow (green), and choroidal blood flow (red) acquired by longitudinal OCTA imaging of eyes. En face angiogram of the outer retina showing the CNV (area demar-
cated by the white dotted boundary) and the choroid with avascular space (area demarcated by the yellow dotted boundary) surrounding the CNV. (D and E) Temporal 
changes in relative CNV volume (D) and avascular volume surrounding the site of laser photocoagulation (E). Error bars represent means ± SD. Each group, n = 10. 
**P < 0.005, ***P < 0.001 versus WT by unpaired Student’s t test.
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and led to choriocapillary regression in the laser-induced CNV 
model.
ABTAA suppresses CNV and vascular leakage
To investigate the therapeutic effect of Tie2 activation on NV-AMD, 
ABTAA (5 g each) was intravitreally administered to mice at D1 as 
a prevention phase (Fig. 4A). As a control or for comparison, Fc or 
VEGF-Trap (5 g each) was administered in the same manner as 
that for the mice (Fig. 4A). To recapitulate a clinical scenario, the 
same treatments were performed at D7 as for a treatment phase 
(Fig. 4E). CNV volumes of the RPE-choroid-sclera flat mounts were 
calculated in both phases at D14. Consistent with a previous report 
(29), VEGF-Trap effectively reduced CNV volume by 63.0% (pre-
vention phase; Fig. 4, B and C) and induced CNV regression by 
64.4% (treatment phase; Fig. 4, F and G) compared with Fc. ABTAA 
similarly attenuated CNV volume (64.1%) in the prevention phase 
and induced CNV regression (65.3%) in the treatment phase (Fig. 4, 
B, C, F, and G). Combined fluorescein angiography (FA) and indo-
cyanine green angiography (ICGA) enabled us to measure vascular 
leakage at the neovessels around the laser injury site. Compared 
with Fc, both VEGF-Trap (52.8 and 37.0%) and ABTAA (44.3 and 
38.3%) similarly suppressed vascular leakage in both phases (Fig. 4, 
B, D, F, and H). Notably, the Fc-treated group showed no significant 
difference in vascular leakage between D6 and D14 in the treatment 
phase, but VEGF-Trap and ABTAA markedly reduced vascular 
leakage (45.6 and 50.0%, respectively) (Fig. 4, F and H). Thus, the 
magnitude of the suppression of CNV and vascular leakage was 
quantitatively indistinguishable between VEGF-Trap and ABTAA 
in the mouse model of laser-induced CNV.
ABTAA-induced Tie2 activation regenerates the 
choriocapillaris, leading to reduction of the avascular space 
surrounding the CNV lesions
To examine the effect of ABTAA-induced Tie2 activation on cho-
riocapillary regeneration in the avascular space surrounding the site 
of laser injury from the initial period of CNV formation, we per-
formed intravitreal injection of Fc, VEGF-Trap, or ABTAA (5 g 
each) into mice at D1 (fig. S6A). Intravital OCTA was performed at 
D7, D14, D21, and D35 (fig. S6A), and the relative avascular volume 
surrounding the site of laser injury was calculated from en face im-
ages exhibiting the choroidal layer. There was a slight reduction in 
the avascular volume in choroids treated with Fc, whereas ABTAA 
gradually but markedly reduced the avascular volume by 26.9, 34.2, 
and 38.6% at D14, D21, and D35, respectively (fig. S6, B, D, and E). 
In contrast, VEGF-Trap somewhat increased the avascular volume 
by 35.9, 28.3, and 47.5% at D14, D21, and D35, respectively (fig. S6, 
B, C, and E).
To determine the effect of ABTAA on choriocapillary regenera-
tion after establishment of CNV, we intravitreally administered Fc, 
VEGF-Trap, or ABTAA (5 g each) to mice at D7, and intravital 
OCTA was performed at D6, D14, D21, and D35 (Fig. 5A). Similar 
to the results in the prevention phase, a slight reduction in the avas-
cular volume was observed in choroids treated with Fc. Choroids in 
ABTAA-treated eyes showed serial and profound reduction in the 
avascular volume by 30.1, 36.4, and 37.0% at D14, D21, and D35, 
respectively (Fig. 5, B, D, E). However, choroids in VEGF-Trap–
treated eyes showed an avascular volume increase by 11.4, 16.0, and 
18.1% at D14, D21, and D35, respectively (Fig. 5, B, C, and E). Over-
all, these findings indicate that ABTAA promotes regeneration of 
the choriocapillaris, while VEGF-Trap led to choriocapillary regres-
sion in the laser-induced CNV model.
ABTAA forms a complex with Angpt2 and Tie2 in the mouse 
CNV model
To investigate further how intravitreal ABTAA exerts therapeutic 
effects on NV-AMD, we then examined vitreal levels of Angpt2 and 
expression of Angpt2 and Tie2 in ECs of the CNV after laser photo-
coagulation. Vitreal Angpt2 concentration had increased 1.8-fold at 
D1 after laser injury and further increased by 2.1- to 2.2-fold at D3 
and D5 (fig. S7, A and B), which is consistent with what is seen in 
patients with NV-AMD (30). The source of the increased Angpt2 
was likely the diseased ECs because high expression of Angpt2 
was selectively confined to the ECs of the CNV (fig. S7, C and D). The 
administered ABTAA was highly detectable in the Tie2- expressing 
ECs of the CNV (fig. S7, E to G). These findings imply that ABTAA 
binds to Angpt2 in the vitreal cavity and that this complex leads to 
binding, clustering, and activation of Tie2 by forming the triple com-
plex of ABTAA-Angpt2-Tie2 (19) in ECs of the CNV and chorio-
capillaris. Meanwhile, no differences in the relative volumes of CNV 
and the avascular space surrounding the site of laser injury were 
found between the ABTAA-treated eye and the Fc-treated eye in the 
Tie2iEC mice (fig. S8, A to E), indicating that the action of ABTAA 
was mediated entirely through Tie2.
ABTAA alleviates hypoxia and favorably alters gene 
expression profiles in CNV lesions and the surrounding 
RPE-choroid complex
To address the beneficial effects of vascular alterations induced by 
ABTAA, we analyzed changes in hypoxia and hypoxia-related gene 
expression profiles at the CNV area and the surrounding RPE- 
choroid complex. Intravitreal administration of Fc, VEGF-Trap, or 
ABTAA (5 g each) was performed in mice at D1, and the extent of 
hypoxia was measured by pimonidazole staining at D4 (Fig. 6A). 
ABTAA reduced the hypoxic area by 41.2% compared with Fc, 
whereas VEGF-Trap increased the hypoxic area by 32.4% (Fig. 6, 
B and C). RNA sequencing (RNA-seq) analysis of CNV lesions and 
surrounding tissues collected by laser capture microdissection re-
vealed a markedly different pattern in response to ABTAA com-
pared to the response to VEGF-Trap (fig. S9, A and B). In particular, 
the specific genes related to hypoxia were up-regulated by VEGF-
Trap, whereas they were down-regulated by ABTAA (fig. S9C). Gene 
set enrichment analysis (GSEA) also identified that VEGF-Trap re-
sulted in enrichment of genes up-regulated under hypoxic condi-
tions in comparison to ABTAA (fig. S9D). In addition, differentially 
expressed genes (DEGs) in each condition (adjusted P < 0.05) were 
subjected to ingenuity pathway analysis (IPA) to allow for interpre-
tation of the details associated with disease and biological function. 
Most hypoxia-induced terms were significantly enriched by VEGF-
Trap, with up-regulation of terms related to cell death and apoptosis 
and suppression of terms related to cell proliferation, migration, and 
movement (fig. S9E and table S1). In contrast, ABTAA relieved the 
adverse effects of VEGF-Trap such as cell death and apoptosis and 
specifically suppressed cell death of retinal cells and apoptosis of RPE 
cells (fig. S9F and table S1). In addition, ABTAA promoted sprout-
ing angiogenesis, cell movement, and viability (fig. S9F and table S1), 
implying that ABTAA-induced regeneration of the choriocapillaris 
facilitated the relief of hypoxia to provide a favorable microenviron-
ment in the RPE and choroidal tissues of NV-AMD.
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Fig. 4. ABTAA inhibits CNV formation and leads to CNV regression and vascular leakage suppression. (A and E) Diagram of schedule for induction of CNV at D0; 
intravitreal administration of Fc, VEGF-Trap, or ABTAA (5 g each) at D1 (prevention phase) or D7 (treatment phase); and their analyses at D6 (treatment phase) and/or 
D14 (both phases). (B and F) Images of late-phase FA to detect vascular leakage surrounding the site of laser injury and ICGA and CD31 staining of RPE-choroid-sclera flat 
mounts to quantify the extent of CNV at D14 (both phases). (C and G) Comparisons of CNV volumes calculated as total CD31+ volume at the site of laser photocoagulation. 
Error bars represent means ± SD. Each group, n = 11. ***P < 0.001 by one-way analysis of variance (ANOVA) followed by Student-Newman-Keuls post hoc test. (D and 
H) Comparisons of leaky areas around CNV calculated as the total measured hyper-fluorescent areas in FA images divided by the total measured CNV areas in ICGA images. 
Error bars represent mean ± SD. Each group, n = 11. ***P < 0.001 by one-way ANOVA followed by Student-Newman-Keuls post hoc test; ###P < 0.001 by paired Student’s 
t test. VT, VEGF-Trap; AT, ABTAA; n.s., not significant. Scale bars, 100 m.
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DISCUSSION
In this study, we demonstrate that Angpt-Tie2 signaling is critical 
for maintaining the adult choriocapillaris. Impairment of this system 
leads to choriocapillary loss, a major causative event in NV-AMD 
(2, 13). The most intriguing finding of this study is that ABTAA- 
induced Tie2 activation not only inhibited CNV with suppression 
of vascular leakage but also promoted regeneration of the chorio-
capillary vascular network, which is the critical step for fundamen-
tal recovery of NV-AMD (Fig. 6D). The regenerated choriocapillary 
vasculature subsequently alleviates hypoxia, leading to a favorable 
transition of the CNV microenvironment to prevent recurrence of 
NV-AMD. Thus, Tie2 activation by ABTAA represents an alterna-
tive, combinative therapeutic strategy for treating patients with NV- 
AMD with alleviation of the adverse effects that can arise from 
long-term treatment with VEGF blockade.
AMD is subdivided into two types: dry AMD and NV-AMD. For 
the past decades, impairment of the RPE has been considered as a 
principal player in the development of dry AMD (31). Dry AMD 
results from a gradual loss of RPE cells and the accumulation of druse-
noid deposits, subsequently inducing photoreceptor degeneration 
Fig. 5. ABTAA promotes regeneration of choriocapillaris surrounding the site of laser photocoagulation in the treatment phase. (A) Diagram of schedule for in-
duction of CNV at D0, intravitreal administration of Fc, VEGF-Trap, or ABTAA (5 g each) at D7 and intravital OCTA at D6, D14, D21, and D35 (treatment phase). (B to D) En 
face OCT angiograms and selected cross-sectional OCT angiograms of the locations indicated by white dotted lines showing inner retinal blood flow (blue), outer retinal 
blood flow (green), and choroidal blood flow (red) acquired by longitudinal OCTA imaging of eyes treated with Fc, VEGF-Trap, and ABTAA. En face angiogram of the 
outer retina showing the CNV (area demarcated by the white dotted boundary) and the choroid with the avascular space (area demarcated by the yellow dotted bound-
ary) surrounding the CNV. (E) Temporal changes in relative avascular volumes surrounding the site of laser photocoagulation. Error bars represent means ± SD. Each 
group, n = 11. *P < 0.05, **P < 0.005 versus Fc by one-way ANOVA followed by Student-Newman-Keuls post-test.
 o
n
 April 15, 2019
http://advances.sciencem
ag.org/
D
ow
nloaded from
 
Kim et al., Sci. Adv. 2019; 5 : eaau6732     13 February 2019
S C I E N C E  A D V A N C E S  |  R E S E A R C H  A R T I C L E
9 of 16
and choriocapillary loss (2). On the other hand, emerging evidences 
in patients with NV-AMD and postmortem human eyes demon-
strated that the area of choriocapillary loss extends beyond the mar-
gin of RPE loss (2, 13, 32), indicating that the loss and dysfunction 
of choriocapillaris is the main cause of NV-AMD. This leads to ex-
cessive production of VEGF-A from the relatively intact RPE cells 
that are exposed to extreme hypoxia, oxidative stress, and inflam-
mation, which consequently leads to the breakdown of the blood- 
retinal barrier and develops CNV (2). In this regard, we focused on 
analyzing mainly the choriocapillaris because we investigated the 
molecules targeting the choriocapillaris, not the RPE, and the patho-
genesis of NV-AMD driven by loss of the choriocapillaris. The cho-
riocapillaris consists of a continuous layer of fenestrated, highly 
permeable choriocapillary ECs (33). Although the choroid has the 
largest blood flow by weight of all organs, only ~11% of choriocap-
illaris are ensheathed by pericytes, a key regulator of vascular stability, 
whereas the capillaries in other organs are ensheathed by 34 to 95% 
(12, 34). While the sparse pericyte ensheathment may contribute to 
Fig. 6. ABTAA reduces hypoxia in RPE-choroid complex surrounding the CNV lesions. (A) Diagram of schedule for induction of CNV at D0; intravitreal administration 
of Fc, VEGF-Trap, or ABTAA (5 g each) at D1; and their analyses at D4. (B) Images of pimonidazole staining to detect hypoxia in CNV and the surrounding RPE-choroid 
complex (area demarcated by the white dotted boundary) at the site of laser injury. Scale bars, 100 m. (C) Comparisons of pimonidazole+ hypoxic areas. Error bars rep-
resent means ± SD. Each group, n = 10. *P < 0.05, **P < 0.005 versus Fc by one-way ANOVA followed by Student-Newman-Keuls post-test. (D) Schematic diagrams depict-
ing how ABTAA functions as an alternative, combinative treatment of NV-AMD. In normal eyes, the outer retinal layers including the RPE are supplied by diffusion from 
the choriocapillaris. NV-AMD is featured by the development of CNV, leading to vascular leakage and macular edema. In NV-AMD, loss of choriocapillary causes hypoxia 
in RPE and adjacent cells, which induces the production of VEGF, a key player in leaky neovascularization. VEGF blockades, the current treatment of choice, effectively 
inhibit CNV and macular edema. However, because VEGF has a central role in the maintenance of choriocapillaris, VEGF blockades could aggravate the hypoxic environ-
ments by further promoting the loss of choriocapillaris and RPE damage. On the other hand, ABTAA-induced Tie2 activation not only inhibits CNV and suppresses vascu-
lar leakage but also promotes regeneration of choriocapillaris, subsequently alleviating hypoxia and leading to a favorable transition of the CNV microenvironment to 
prevent recurrence of NV-AMD.
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structural plasticity of the choriocapillaris in response to physiolog-
ical changes, it could also be a cause of unavoidable vulnerability 
and instability in response to various pathologic insults (12, 34, 35). 
Along with previous reports demonstrating that the decrease in 
choroidal blood flow by ~20% is associated with increasing risk 
for CNV development (36) and that the number of fenestrations in 
choriocapillary ECs is greatly decreased in eyes of human patients 
with AMD (13), the present results revealed that impaired Angpt-
Tie2 signaling impedes maintenance of choriocapillary integrity, 
induces visual impairment, exacerbates CNV formation, and pre-
vents choriocapillary regeneration surrounding the CNV lesions. In 
this regard, Tie2 activation could be a fundamental therapeutic ap-
proach for inhibiting recurrence of NV-AMD through recovery 
of choroidal circulation sufficient to meet the metabolic demand of 
the outer retina. We demonstrate that Tie2 activation through in-
travitreal administration of ABTAA induces choriocapillary regen-
eration, not to mention suppression of CNV and vascular leakage.
The mechanism for maintaining the choriocapillaris in the ro-
dents is not well known despite its importance in the pathogenesis 
of NV-AMD (2, 13, 14). Although conditional knockout mouse mod-
els targeting Tie2 and Angpt1 exhibited a glaucoma phenotype (25), 
it is reasonable to conclude that the elevated IOP in these genetic 
mice models was not responsible for the decreased choroidal blood 
flow; we demonstrated that choroidal blood flow was not changed 
in the microbeads-induced ocular hypertension model, and an IOP 
of up to 50 mmHg does not affect the volume of choroidal blood 
flow in cases of rat or human (37, 38). In addition, there have been 
no suitable imaging tools for definitive visualization of the choroidal 
vasculature and quantifiable in vivo measurements for longitudinal 
analysis. Conventional dye-based two-dimensional angiography has 
limited axial resolution and problems distinguishing vascular abnor-
malities within different layers. Meanwhile, confocal immunofluo-
rescence (IF) studies suffer from blocked fluorescence due to the RPE, 
a highly pigmented layer that absorbs excess light, and the impossi-
bility of longitudinal follow-up in the same subject. Compared with 
previous measures, our laboratory-built high-speed OCTA system 
has several advantages. First, use of a wavelength-swept laser cen-
tered at 1048 nm allowed enough imaging penetration depth for 
clear visualization of the choroidal layer. Second, a wavelength tun-
ing range of ~94 nm provided enough axial resolution for exact 
quantification of the area of retinal and choroidal vessels and the 
volume of CNV and avascular space in mice. Third, high-speed im-
aging with a repetition rate of 230 kHz enabled acquisition of full 
volumetric scans over a sufficiently large area without significant 
motion artifacts by application of a subpixel motion compensation 
algorithm (39). Fourth, the shadow projection artifacts underneath 
the thick retinal vessels caused by rapid attenuation of the OCTA 
signal in depth were shaded in another color, and the voxel of the 
shadow artifacts was excluded from the image analyses that were 
conducted automatically. Last, OCTA enables longitudinal measure-
ments that allow normalization of CNV volumes and avascular space, 
which can prominently reduce the number of animals required by 
diminishing the effect of inherent variation in CNV sizes (40).
Tie2 activation may provide potential therapeutic benefits for 
treating microvascular diseases (15, 18). It not only suppresses vas-
cular destabilization and disseminated intravascular coagulation in 
experimental sepsis mice models (19, 41) but also induces tumor 
vessel normalization in multiple tumor mouse models (20). We and 
others have found that Angpt-induced Tie2 activation plays crucial 
roles in the formation of Schlemm’s canal and maintenance of its 
integrity; in addition, impairment or attenuation of the Angpt- Tie2 
system is implicated in congenital and primary open-angle glauco-
ma (25, 42, 43). Notably, Tie2 activation through ABTAA can reju-
venate the aged Schlemm’s canal and reverse its regression (25), 
leading to enhanced drainage of aqueous humor outflow and re-
duced IOP for the fundamental treatment of primary open-angle 
glaucoma. Notably, a recent report (44) indicates that formation of 
the fenestrated ascending vasa recta, a specialized lymphatic hybrid 
vessel for urine concentration in the renal medulla, requires Angpt-
Tie2 signaling. Given the extraordinarily specialized microenvironment 
of the renal medulla, Angpt-Tie2 signaling could be continuously 
required to maintain integrity of the ascending vasa recta.
Previously, several Tie2 agonists were developed to address the 
unmet need for treating NV-AMD. Although intravitreal COMP-
Angpt1 provides benefits in NV-AMD by suppressing CNV and its 
vascular leakage in the NV-AMD model (16), it involves limitations on 
production, efficacy, and half-life (19). Subcutaneous or intravitreal 
administration of the specific VE-PTP inhibitor AKB-9778, which 
indirectly activates Tie2 by inhibition of its dephosphorylation, leads 
to suppression of CNV (17). However, AKB-9778 may also indi-
rectly induce activation of other receptor tyrosine kinases including 
VEGFR2 in a context-dependent manner (45). Angpt2- blocking anti-
bodies are also being developed for treating patients with pathological 
retinal/choroidal angiogenesis and solid tumors. Although these 
antibodies significantly suppress CNV (46), they secondarily cause 
hypoxia and subsequently enhance expression of VEGF and Angpt2 
during pathologic angiogenesis (47). Thus, ABTAA offers more ad-
vantages over these agents because of its dual function of Angpt2 
blockade and Tie2 activation, long-term half-life, and convenient 
production for clinical purposes (19).
Our collective evidence elucidates the essential role of the Angpt-
Tie2 system in maintaining the choriocapillaris in the context of 
NV-AMD. The distinguishing characteristics of ABTAA of favor-
ably altering the CNV microenvironment by regenerating the cho-
riocapillaris make it a novel alternative, combinative therapeutic 
option for filling in the gaps in current anti-angiogenic therapies. 
Further research to demonstrate its efficacy and safety in clinical trials 
remains to be done.
MATERIALS AND METHODS
Study design
The primary aims of the present study were to investigate whether 
the Angpt-Tie2 system is essential for the maintenance of chorio-
capillaris during adulthood with regard to the pathogenesis of NV-
AMD and to evaluate the effect of Tie2 activation in suppressing 
CNV and vascular leakage and regenerating choroidal vasculatures 
of NV-AMD. To achieve our first aim, we initially compared the 
TIE2 level and density of choriocapillaris between healthy young and 
old adults using the cadaveric donor eyes. Then, we made transgenic 
mouse models to deplete Tie2 or Angpt1 and analyzed their cho-
riocapillaris, photoreceptors, and visual functions. In addition, we 
induced CNV in these mice by laser photocoagulation and analyzed 
the extent of CNV formation and the avascular space surrounding 
the CNV. To accomplish our second objective, mice were randomized 
after laser photocoagulation-induced CNV formation for antibody 
administration, and we intravitreally administered a Tie2-activating 
antibody named ABTAA in both therapeutic and preventive settings. 
 o
n
 April 15, 2019
http://advances.sciencem
ag.org/
D
ow
nloaded from
 
Kim et al., Sci. Adv. 2019; 5 : eaau6732     13 February 2019
S C I E N C E  A D V A N C E S  |  R E S E A R C H  A R T I C L E
11 of 16
CNV volume, vascular leakage, and regeneration of choriocapillary 
vascular network were monitored, and changes in gene expression 
profiles in the CNV and surrounding tissues were analyzed. No sta-
tistical method was used to predetermine the sample size. Animals 
or samples were not randomized during experiments. Only male 
mice were used in adult experiments. The investigators were blinded 
to the genotypes of animals during experiments. The investigators 
performing the subsequent analyses including morphometric, func-
tional, and biochemical analyses were blinded to the information 
about treatment groups.
Sampling of human choroids
Anonymous human choroid samples were obtained from the retino- 
choroidal layer of healthy cadaveric donor eyes (Eversight, Ann 
Arbor, USA) left over from corneal transplantation surgery in the 
Samsung Medical Center. These were exempted from a formal re-
view of the institutional review board at the Samsung Medical Center 
because of the lack of patient identifiers and the intention of being 
otherwise discarded. The protein expression of TIE2 was examined 
in the choroid of these samples using IF staining.
Mice
Specific pathogen–free (SPF) C57BL/6 J mice (#000664), Tie2-GFP 
mice (#003658), and Ubiquitin-Cre-ERT2 mice (#007001) were pur-
chased from the Jackson Laboratory. Angpt2-EGFP mice (Tg [Angpt2- 
EGFP] DJ90Gsat/Mmcd) were purchased from the Mutant Mouse 
Regional Resource Centers. Angpt1-GFP (21), Tie2flox/flox (22), and 
Angpt1flox/flox (27) mice were transferred and bred in our SPF ani-
mal facilities at Korea Advanced Institute of Science and Technology 
(KAIST). VE-cadherin-Cre-ERT2 mice (23) were mated with Tie2flox/flox 
mice to obtain EC-specific Tie2-deleted mice in a tamoxifen- dependent 
manner. To deplete Angpt1 globally, Angpt1flox/flox mice were crossed 
with Ubiquitin-Cre-ERT2 mice. Two milligrams of tamoxifen (T5648, 
Sigma-Aldrich) was injected intraperitoneally a total of three times 
every 2  days to 8-week-old genetically modified mice. All mice 
were fed with free access to a standard diet (PMI LabDiet) and wa-
ter. All mice were anesthetized by an intramuscular injection of keta-
mine (40 mg/kg) and xylazine (12 mg/kg) before any procedures. All 
animal care and experimental procedures were carried out in ac-
cordance with the protocol approved by the Institutional Animal 
Care and Use Committee of KAIST (no. KA2015-15), and mice 
were handled according to the Association for Research in Vision 
and Ophthalmology Statement for the Use of Animals in Ophthal-
mic and Vision Research.
PCR to genotype for photoreceptor degeneration mutations
For DNA extraction, tail tissue was heated in 200 l of chelex re-
agent (10% chelex, 0.1% Tween 20, and 1% proteinase K) for over 
3 hours at 65°C, followed by proteinase K inactivation for 15 min at 
75°C. For the polymerase chain reaction (PCR) reaction, 4 l of the 
supernatant was placed into 16 l of reaction mixture consisting of 
the AccuPower Taq PCR Master Mix (K-2609; Bionner) and for-
ward and reverse primers (Macrogen). The DNA of cng3, abca4, 
and pde6b genes was amplified by PCR, and WT and mutant bands 
were detected as previously described (48, 49).
Laser-induced CNV mouse model
Generation of the laser-induced CNV mouse model was performed 
according to a previously described method (28) with some modifi-
cations (16). Approximately 8-week-old male mice were used for gen-
eration of CNV. After dilating pupils with phenylephrine (5 mg/ml) 
and tropicamide eye drops (5 mg/ml; Santen Pharmaceutical) and 
instillation with 0.5% proparacaine hydrochloride eye drops (Alcon) 
for topical anesthesia, laser photocoagulator (Lumenis Inc.) with a 
slit lamp delivery system was used with a glass coverslip as a contact 
lens to visualize the retina. Sufficient laser energy (wavelength, 
532 nm; power, 250 mW; duration, 100 ms; spot size, 50 m) was 
delivered to four locations for each eye (the 3, 6, 9, and 12 o’clock 
positions of the posterior pole). Only burns that produced a bubble 
at the time of laser photocoagulation, indicating the rupture of the 
Bruch’s membrane, were included in this study. Spots containing 
hemorrhage at the laser site were excluded from the analysis.
ELISA for Angpt2 in vitreal fluid of mouse
Vitreous fluid in mouse eye was sampled using the Nanoliter 2000 
microinjector (World Precision Instruments) fitted with a glass cap-
illary pipette. The concentration of Angpt2 in the vitreal fluid was 
measured using a mouse/rat Angpt2 enzyme-linked immunosorbent 
assay (ELISA) kit (R&D Systems) according to the manufacturer’s 
instructions, and the optical density was measured using a Spectra 
MAX340 plate reader (Molecular Devices).
Intravitreal administration
To intravitreally administer indicated reagents, ~1 l containing 5 g 
of each reagent was injected into the vitreal cavity using the Nanoliter 
2000 microinjector fitted with a glass capillary pipette.
Confocal scanning laser FA and ICGA
Using our custom-built confocal scanning laser retinal angiography 
system (50), in vivo fundus FA and ICGA of the CNV lesion were 
performed. Continuous-wave laser modules at 488 and 785 nm were 
used as excitation sources for fluorescein and ICG, respectively. A 
raster-scanning pattern of excitation lasers was achieved by a scanner 
system consisting of a rotating polygonal mirror (MC-5; Lincoln 
Laser) and a galvanometer-based scanning mirror (6230H; Cambridge 
Technology) and delivered to the back aperture of an imaging lens. 
A high–numerical aperture (NA) objective lens (PlanApo , NA 
0.75; Nikon) was used as the imaging lens to provide wide-field fun-
dus fluorescence images. Fluorescence signals detected by photo-
multiplier tubes (R9110; Hamamatsu Photonics) were digitized by a 
frame grabber and reconstructed to images with a size of 512 × 512 
pixels per frame in real time. To visualize late-phase (6 min) FA and 
ICGA images using the angiography system, 10 mg of fluorescein 
sodium (Alcon) and 0.15 mg of ICG (Daiichi Pharmaceutical) were 
administered intraperitoneally and intravenously, respectively. The 
imaging procedure was performed under systemic anesthesia and 
pupil dilation to improve the quality of images. Leaky areas from 
CNV were calculated as the total measured hyperfluorescent areas 
in FA images divided by the total measured CNV areas in ICGA 
images using a Java-based imaging software (ImajeJ, NIH; available 
at http://rsb.info.nih.gov/ij).
Histological and morphometric analyses
IF analyses of the RPE-choroid-sclera flat mounts were performed 
as previously described (16). Enucleated eyes were fixed with 4% para-
formaldehyde for 30 min at room temperature (RT). For IF staining 
of sectioned retina and choroid, fixed eyeballs were then dehydrated 
in 20% sucrose solution overnight, embedded in tissue-freezing 
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medium (Leica), and cut into 20-m sections. Samples were blocked 
with 5% donkey or goat serum in PBST (0.3% Triton X-100 in phosphate- 
buffered saline) and then incubated in blocking solution with one 
or more of the following antibodies at 4°C overnight: rabbit anti- 
human CD31 polyclonal antibody (#AB32457, abcam), goat anti- 
human Tie2 polyclonal antibody (#AF313, R&D systems), hamster 
anti-mouse CD31 monoclonal antibody (#MAB1398Z, clone 2H8, 
Millipore), goat anti-mouse Tie2 polyclonal antibody (#AF762, R&D 
systems), chicken anti-GFP polyclonal antibody (#AB16901, Millipore), 
rat anti-mouse CD144 monoclonal antibody (#740933, clone 11D4.1, 
BD Biosciences), rabbit anti-mouse opsin polyclonal antibody 
(#AB5405, Millipore), and rabbit anti-mouse rhodopsin monoclonal 
antibody (#27182, clone D4B9B, Cell Signaling Technology). After 
several washes, the samples were incubated for 4 hours at RT with 
the following secondary antibodies (Jackson ImmunoResearch Lab-
oratories): fluorescein isothiocyanate (FITC)– or Cy5-conjugated 
anti-hamster immunoglobulin G (IgG), FITC- or Cy3-conjugated 
anti-rabbit IgG, FITC- or Cy3-conjugated anti-goat IgG, FITC- 
conjugated anti-chicken IgG, and Cy3-conjugated anti-human 
IgG. Samples were mounted with fluorescent mounting medium 
(VectaShield H-1000; Vector Laboratories), and IF images were ac-
quired with a confocal microscope (LSM880; Carl Zeiss Microscopy). 
CD31+ CNV volumes were measured using the MATLAB image 
processing toolbox (MATLAB 8.1; MathWorks), which are pre-
sented in cubic micrometers. The volume of CNV in one eye was 
averaged to give one experimental value. Morphometric analyses of 
choriocapillaris were performed using ImageJ software (NIH). The 
relative area of choriocapillaris was calculated as a percentage of the 
CD31+ area divided by its control area. To quantify the expression 
of Tie2 and CD144, intensities were measured in the CD31+ chorio-
capillary area. To perform IF staining for hypoxia, mice were intra-
peritoneally injected with pimonidazole hydrochloride (60 mg/kg) 
in PBS (Hypoxyprobe Green Kit; Hypoxyprobe) and sacrificed after 
1 hour. An FITC-conjugated monoclonal antibody against pimonidazole 
was used for IF staining of the flat-mounted RPE-choroid-sclera 
complex. For statistical analysis, values from four random spots at 
the center of the choroid in each eye were averaged. For comparison 
of staining intensities, the values were normalized by the background 
signals in nonvascularized regions, and their ratios were normal-
ized by control and presented as percentages.
Optical coherence tomography angiography
The retino-choroidal layers were imaged using a prototype high-
speed swept-source optical coherence tomography (OCT) system 
(40), using a custom ring cavity wavelength-swept laser centered at 
1048 nm with an A-scan rate of 230 kHz. OCT images were collect-
ed in a 1.7 mm by 1.7 mm field of view within the retino-choroidal 
layer to monitor regeneration of choroidal vasculatures at the site 
of laser photocoagulation after intravitreal injection of reagents. To 
obtain cross-sectional OCT angiograms, which allows for selective 
visualization of blood vessels without the retinal and choroidal pa-
renchyma, we compared repeatedly recorded B-scan images and 
detected pixel-by-pixel intensity decorrelation of those images that 
are mainly caused by movement of erythrocytes inside the vessels. 
Then, by using automatic layer flattening and segmentation algo-
rithms, cross-sectional OCT angiograms were flattened to the RPE, 
and en face OCT angiograms were generated by separate projection 
of each flattened cross-sectional OCT angiogram in three depth 
ranges: inner retinal, outer retinal, and choroidal layers (fig. S2). 
The outer plexiform layer and Bruch’s membrane were defined as 
the boundaries separating inner retinal, outer retinal, and choroidal 
layers. Shadow artifacts caused by relatively thick retinal vessels in 
the outer retina and choroid were removed in figures for better 
comparison. Unremoved shadow artifacts caused by major arterioles 
and venules in the inner retina were shaded in blue. The density of 
retina and choroid vessel was automatically calculated as the pro-
portion of measured area occupied by flowing blood vessels defined 
as pixels having decorrelation values above the threshold level. Avas-
cular pixels were detected from the en face OCT angiogram repre-
senting choroidal layers by means of the image processing toolbox 
of a commercial software (MATLAB 8.1; MathWorks). Then, the 
total avascular volume surrounding the laser injury site was calcu-
lated by summing the number of avascular pixels multiplied by the 
volume of one pixel. To analyze the changing complexion of 
avascular volume, serially measured values in each eye were trans-
formed into percentage change from baseline value.
Microbeads-induced ocular hypertension mouse model
The microbeads-induced ocular hypertension mouse model was gen-
erated according to a previously described method (51) with some 
modifications. Approximately 8-week-old male mice were used. Ster-
ilized microbeads (Polybead Microspheres; bead diameter, 1 + 6 m; 
Polysciences Inc.) in 100% ethanol were washed and resuspended in 
PBS. After topical anesthesis by instillation with 0.5% proparacaine 
hydrochloride eye drops, ~4 l containing 2 l of equal volume mix-
ture of two-sized microbeads (3 × 106 beads/l for 6 m beads and 
1.5 × 107 beads/l for 1 m beads) and 2 l of viscoelastic solution 
[sodium hyaluronate (18 mg/ml), Megacrom; Woojeon Co. Ltd] 
was injected into the anterior chamber using the Nanoliter 2000 mi-
croinjector fitted with a glass capillary pipette. Because the visco-
elastic solution entered last into the anterior chamber and pushed 
microbeads into the peripheral anterior chamber, reflux of micro-
beads was prevented after withdrawal of the glass capillary pipette. 
IOP measurements were performed with a rebound tonometer 
(Tonolab; Tiolat), as previously described (25).
Electroretinogram
To assess the retinal neuronal function at indicated time points, 
a full-field electroretinogram was recorded in the indicated mice 
using Phoenix Micron IV system (Phoenix Research Labs). Mice 
were dark- or light-adapted for 12 hours before electroretinogram 
monitoring, anesthetized, and placed on a heating pad to maintain 
body temperature. After pupil dilatation by one-time topical ap-
plication of a 0.5% tropicamide/0.5% phenylephrine mixed eye 
drop (Mydrin-P, Santen, Osaka, Japan), the cornea was located by 
gold-plated objective lens, and silver-embedded needle electrodes 
were located at the forehead (reference) and tail (ground). Using 
LabScribeERG software (Version 3, Phoenix Research Labs), the 
stimulus and recording of electroretinogram were performed ac-
cording to the manufacturer’s instruction. In the dark-adapted con-
dition (scotopic), rod and mixed cone/rod responses to a series of 
white flashes of increasing intensities ranging from −2.2 to 2.2 log 
(cd·s/m2) with a digital bandpass filter ranging from 0.3 to 1000 Hz 
were recorded. In the light-adapted condition (photopic) with 1.3 log 
(cd·s/m2) background, cone responses to a 1-Hz stimulus ranging 
from 0.4 to 2.2 log (cd·s/m2) with the filter ranging from 2 to 200 Hz 
were recorded. After averaging the signals, the amplitude was pre-
sented by the LabScribeERG software and used for analyses.
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Immunoblot analysis
For protein extraction, harvested retinas of both eyes in each mouse 
were washed with PBS containing protease inhibitor cocktail (Roche). 
Tissues were then homogenized with Precellysis Tissue Homoge-
nizer (Bertin Instruments) in radioimmunoprecipitation assay buf-
fer (Thermo Fisher Scientific) supplemented with DNase I (Roche) 
and protease inhibitor cocktail (Roche). Homogenized samples were 
centrifuged at 15,000 rpm for 20 min at 4°C. Tissue lysate soups 
were then subjected to SDS–polyacrylamide gel electrophoresis 
(PAGE). After electrophoresis, proteins were transferred to nitro-
cellulose membranes. After being blocked for 1 hour with 5% bo-
vine serum albumin (BSA) in TBST (0.1% Tween 20 in tris-buffered 
saline), the membranes were incubated with the following antibod-
ies at 4°C overnight: anti-Tie2 (rabbit polyclonal, catalog no. sc-324, 
Santa Cruz Biotechnology), anti-opsin (chicken polyclonal, catalog 
no. PA1-9517, Thermo Fisher Scientific), anti-rhodopsin (mouse mono-
clonal, clone 1D4, catalog no. ab5417, abcam), and anti-GAPDH 
(glyceraldehyde-3-phosphate dehydrogenase; rabbit monoclonal, clone 
D16H11, catalog no. 5174, Cell Signaling Technology). After washes, 
membranes were incubated with secondary peroxidase-coupled 
antibody at RT for 1 hour. Chemiluminescent signals were devel-
oped using ECL Western blot detection solution (Millipore). Result-
ant bands from four independent experiments were detected with a 
luminescent image analyzer (LAS-1000 mini, Fujifilm), and densi-
tometry quantifications of indicated proteins normalized to GAPDH 
in each lane were compared using ImageJ software (NIH).
Generation of a new version of ABTAA
We generated an advanced version of ABTAA, which recognizes 
the different epitope of human ANGPT2 and has a higher produc-
tion rate in the mammalian cells. The properties of the new version 
of ABTAA were almost similar to the original version of ABTAA 
(19). The new version binds to human ANGPT2 with an equilibrium 
dissociation constant (Kd) value of 0.9 nM (fig. S10A). Furthermore, 
in the presence of ANGPT2 in primarily cultured human umbilical 
vein ECs (HUVECs; Lonza), the ABTAA triggered TIE2 phospho-
rylation and activation of its downstream signals, including Akt and 
extracellular signal–regulated kinase (ERK), in a dose- dependent 
manner (fig. S10B). ABTAA + ANGPT2 also induced TIE2 trans-
location to cell-cell junction and nuclear clearance of FOXO1 in 
common with ANGPT1 (fig. S10, C and D).
Surface plasmon resonance
Surface plasmon resonance analyses were run using a Biacore T200 
(GE Healthcare) instrument. Amine-coupling chemistry was used to 
immobilize anti-human IgG (Fc) antibody on the surface of a CM5 
biosensor chip. Anti-human IgG (Fc) antibody in sodium acetate 
(pH 5.0) was injected over 6 min using a flow rate of 10 l/min and 
gave a surface density of ~11,000 resonance units (RU). Flow cells were 
activated with a 1:1 mixture of 1-ethyl-3-(3-dimethylaminopropyl)
carbodiimide hydrochloride and N-hydroxysuccinimide. Surfaces were 
then blocked by an injection of 1 M ethanolamine-HCl (pH 8.5). 
ABTAA was injected at a flow rate of 5 l/min over 1 min and gave a 
surface density of 220 to 240 RU. A series of concentrations of hu-
man ANGPT2 full-length in HBS-EP buffer (10 mM HEPES, pH 7.4, 
500 mM NaCl, 3 mM EDTA, 0.005% surfactant P20) were injected at a 
flow rate of 30 l/min. The experiment was performed at 25°C with an 
association time of 4 min and a dissociation time of 3 min. After each 
binding cycle, a regeneration solution (3 M MgCl2) was injected for 
30 s at a flow rate of 30 l/min to remove any noncovalently bound 
protein. Signal detection was at a rate of 10 signals/s. Data were evalu-
ated using 1:1 binding model of BIAevaluation software version 1.0.
Immunoprecipitation and immunoblot analysis
HUVECs were purchased from Lonza. The cells were confirmed to 
be mycoplasma-negative (MycoAlert Detection Kit, Lonza), cultured 
in endothelial growth medium (EGM2-MV, Lonza), and incubated 
in a humidified atmosphere of 5% CO2 at 37°C. For TIE2 immuno-
precipitation, HUVECs were seeded into 100-mm culture dishes 
and grown to confluence. HUVECs were starved for 6 hours and 
then incubated with human ANGPT2 (1 g/ml; R&D Systems) in 
the presence of ABTAA for 30 min. Cells were rinsed once with cold 
PBS and lysed in cold complete lysis-M buffer (Roche) containing 
protease and phosphatase inhibitors (Roche). The lysates were 
centrifuged at 14,000 g at 4°C for 15 min, and supernatants were 
subjected to immunoprecipitation with anti-TIE2 antibody (R&D 
systems). The immunoprecipitates were incubated with 20 l of 
Dynabeads Protein G (Life Technologies) for 2 hours. Beads with 
immunoprecipitates were washed three times with cold lysis buffer, 
heated in Laemmli sample buffer at 95°C for 5 min, subjected to SDS- 
PAGE on 4 to 15% Mini-PROTEAN TGX Precast Gels (Bio-Rad), 
transferred to nitrocellulose membrane (Invitrogen), and probed 
with horseradish peroxidase (HRP)–conjugated anti–phosphotyrosine 
4G10 antibody (Millipore). The blots were developed using the ECL 
Western blotting detection kit (GE Healthcare) and visualized with 
Amersham Imager 600 (GE Healthcare). The membranes were 
stripped and reprobed with an anti-TIE2 (Millipore) antibody. The 
primary antibodies for pAKT (S473), AKT, pERK (T202/Y204), and 
ERK (all from Cell Signaling) were used. Secondary HRP-conjugated 
antibodies (Bio-Rad) were used for signal detection.
IF staining for cultured ECs
Cells on an eight-well Lab-Tek II chamber (Nunc) were fixed with 
4% formaldehyde in PBS at RT for 10 min, permeabilized with 
0.1% Triton X-100 in PBS, blocked with 1% BSA in PBS at RT for 
1 hour, and incubated with primary antibodies at RT for 1 hour. 
Primary anti bodies for FOXO1 (Cell Signaling) and TIE2 (R&D 
Systems) were used. The cells were then incubated with secondary 
antibodies (Invitrogen) in the dark at RT for 1 hour and mounted 
with VECTASHIELD mounting medium with 4′,6-diamidino-2- 
phenylindole (Vector Labs). Images were taken with a confocal laser 
scanning microscope (LSM880, Carl Zeiss).
Laser capture microdissection
The RPE-choroidal complex was obtained from enucleated eyes and 
flat-mounted on polyethylene naphthalate membrane (Carl Zeiss). 
CNV and surrounding tissues (twofold larger in diameter than CNV 
itself), including the RPE and choroid, were collected using laser 
capture microdissection (PALM MicroBeam, Carl Zeiss) and sub-
jected to RNA isolation.
RNA isolation, library preparation, and RNA-seq
For RNA isolation, CNV and surrounding tissues of eyes treated with 
Fc, VEGF-Trap, and ABTAA were used. Total RNA was isolated 
using TRIzol reagent (Invitrogen). RNA quality was assessed by an 
Agilent 2100 bioanalyzer using the RNA 6000 Nano Chip (Agilent 
Technologies), and RNA quantification was performed using the ND- 
2000 Spectrophotometer (Thermo Fisher Scientific). For library 
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preparation, the SENSE 3′ mRNA-seq Library Prep Kit (Lexogen Inc.) 
were used according to the manufacturer’s instructions. Briefly, each 
500 ng of total RNA was prepared, oligothymidilate primers contain-
ing an Illumina-compatible sequence at the 5′ end were hybridized 
to the RNA, and reverse transcription was performed. After degrada-
tion of the RNA template, second-strand synthesis was initiated by a 
random primer containing an Illumina-compatible linker sequence at 
its 5′ end. The double-stranded library was purified by using magnetic 
beads to remove all reaction components. The library was amplified to 
add the complete adapter sequences required for cluster generation. The 
finished library was purified of PCR components. High- throughput 
sequencing was performed as single- end 75 sequencing using NextSeq 
500 (Illumina Inc.). For RNA-seq, the SENSE 3′ mRNA-seq reads were 
aligned using Bowtie2 version 2.1.0 (52). Bowtie2 indices were either 
generated from genome assembly sequence or representative tran-
script sequences for alignment to the genome and transcriptome. The 
alignment file was used to assemble transcripts, estimate their abun-
dances, and detect differential expression of genes. DEG was deter-
mined on the basis of counts from unique and multiple alignments 
using EdgeR within R version 3.2.2 (R development Core Team) using 
BIOCONDUCTOR version 3.0 (53). The RT (read count) data were 
processed on the basis of Quantile normalization method using the 
Genowiz version 4.0.5.6 (Ocimum Biosolutions).
Data analysis for RNA-seq
Three biological replicates of each condition were used for analysis. 
Each raw count value was normalized (log 2) and then analyzed by 
a P value of less than 0.05 to determine DEGs in VEGF-Trap– and 
ABTAA-treated groups relative to Fc-treated group. These normalized 
count values were used to generate heatmaps and perform bioinfor-
matics analysis. RNA-seq gene expression heatmap was generated 
with DEGs (P < 0.05) between VEGF-Trap– and ABTAA-treated groups 
using Cluster and TreeView from the Eisen laboratory (54). Then, 
we used protein annotations in Gene Ontology (GO) ID:0001666, 
“response to hypoxia,” to generate a heatmap of hypoxia signature 
genes, which were plotted using Multiple Experiment Viewer from 
The Institute of Genomic Research. For GSEA, a gene set (KIM_
HYPOXIA) from the Molecular Signatures Database 5.2 (www.broa-
dinstitute.org/gsea/ msigdb/) was used for the analysis of hypoxia- 
responsive transcriptomes. To compare biological effects and disease 
pathway outcomes of ABTAA treatment to CNV against VEGF-Trap, 
the set of DEGs was subjected to IPA (Qiagen). For IPA analysis, 
down-regulated DEGs in the VEGF-Trap–treated group and all 
DEGs in the ABTAA- treated group were used. Significance of the 
disease and biological functional terms were tested by the Fisher’s 
exact test P value between DEGs and IPA knowledge base, and the 
activation or inhibition state of each term was determined by the 
activation z-score. The activation z-score reflects the fold change 
of DEGs, which is calculated by dividing the average of normalized 
count values of VEGF- Trap– and ABTAA-treated groups by that 
of Fc-treated group. To generate bar graphs, normalized P values 
(−log10) were scaled in either negative or positive values according 
to their activation z-scores. The P values, activation scores, and gene 
sets are indicated in table S1.
Statistical analyses
Plotted values are shown as means ± SD throughout this study. Sta-
tistical comparisons were performed using R 3.3.0 (The R Founda-
tion for Statistical Computing). Indicated P values were obtained 
using one-way analysis of variance (ANOVA) followed by Student- 
Newman-Keuls multiple comparisons for post hoc test, paired 
Student’s t test, or Mann-Whitney U test.
SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
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Fig. S1. Expressions of Tie2 and Angpt1 in the RPE-choroid complex.
Fig. S2. Generation of en face OCT angiograms for measurement of retinal and choroidal 
blood flow.
Fig. S3. Elevated IOP is not responsible for reduced choroidal blood flow.
Fig. S4. Global Angpt1 deletion in adult mice causes damage and loss of choriocapillaris.
Fig. S5. Loss of cone but not of rod photoreceptor in the eyes of global Angpt1-depleted mice.
Fig. S6. ABTAA promotes regeneration of choriocapillaris surrounding the site of laser 
photocoagulation in the prevention phase.
Fig. S7. ABTAA forms the Angpt2-Tie2-ABTAA complex in the mouse CNV model.
Fig. S8. Analyses of the effects of ABTAA treatment in adult Tie2-depleted mice.
Fig. S9. RNA-seq analysis of CNV lesions and surrounding tissues treated with VEGF-Trap and 
ABTAA.
Fig. S10. ABTAA binds to ANGPT2 and activates TIE2 and its downstream effectors.
Table S1. List of disease and biological function signatures identified by IPA in the CNV lesions 
and the surrounding RPE-choroid complex treated with VEGF-Trap or ABTAA, related to fig. S9 
(E and F).
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